Cooperative Agreement to Support Activities Related to Analgesics, Anesthetics, and Addiction (U01) Clinical Trials Allowed
Last verified by NonDilute: 2026-04-29. Official notice and agency instructions control.
If you run a clinical research center or academic medical institution with infrastructure for multi-site pain or addiction trials, FDA is offering cooperative funding with significant agency partnership.
Report stale or inaccurate summary
What this is
This is an FDA-administered cooperative agreement (U01 mechanism) designed to fund clinical trial activities investigating analgesics, anesthetics, and addiction-related interventions. The U01 mechanism typically indicates substantial federal involvement and mentorship alongside grant funding. While specific budget ranges and detailed eligibility criteria are not provided in this announcement, this type of funding generally targets established research institutions and clinical networks capable of executing rigorous human-subjects trials. Solo founders and early-stage startups are unlikely to be competitive without institutional partnerships.
Who can apply
Eligibility details are unspecified in this notice. Cooperative agreements (U01) typically require institutional capacity for clinical research, IRB oversight, and patient recruitment. Likely eligible: universities, teaching hospitals, non-profit research organizations, and established clinical networks. Solo founders and small startups without clinical trial infrastructure are unlikely to qualify.
Topics: clinical trials · analgesics · anesthetics · addiction research · fda cooperative agreement · pain management
Public-source funding discovery only. This summary is generated from public agency data and may be incomplete or stale. NonDilute is not affiliated with, endorsed by, or acting on behalf of any government agency. Official notices and agency instructions control. NonDilute does not determine eligibility, provide grant-writing advice, or guarantee funding.